Almirall raises its profits by 36% up to September

BarcelonaThe Catalan pharmaceutical company Almirall earned 53.3 million euros in the first nine months of 2026, 36.3% more than in the same period of the previous year, while its net sales increased by 8.3%, reaching 889.2 million, due to the good performance of its dermatology business in Europe. The company, controlled by the Gallardo family, published its accounts from January to September this Monday with the National Securities Market Commission (CNMV).

Almirall's total revenue, which includes net sales and other categories, amounted to 893.6 million euros, 8.2% more than in the first nine months of 2025. Almirall states that, in normalized terms, its result was a profit of 60.6 million euros, 46% more than between January and September 2025. Regarding operating profit or EBITDA, it has risen by 22.7%, to 221.7 million euros, with a margin of 24.9% on sales, compared to 22% in the same period of the previous year.

The pharmaceutical company highlights the performance of its dermatology business, whose sales have increased by 17.6%, contributing 568.6 million euros in revenue. Of this amount, a total of 520.3 million euros corresponds to the dermatology business in Europe, which is also growing by 17.6%.

Across the continent, sales were driven by the performance of Ilumetri (+11.5%), its treatment for psoriasis, and Ebglyss (+75%), for atopic dermatitis. While the dermatology business accounts for 64% of Almirall's total global sales, general medicine and over-the-counter (OTC) products represent the remaining 36%. "By market, Europe concentrated 91.5% of total sales, contributing 814.1 million euros, while Almirall generated about 30.9 million in the US, 3.5% of total sales, and a total of 44.2 million in the rest of the world, 5%.

More investment in R&D

Research and development (R&D) expenditure up to September amounted to 107.1 million euros, 4.6% more than the same period last year. This investment is equivalent to 12% of the company's net sales, as expected.

General and administrative expenses remained practically stable, at 365.7 million, compared to 366.7 million in the first nine months of 2025. Regarding financial debt, it stood at 285.1 million, 1.4% higher.